# Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

> **NCT04846881** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 611 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Iclepertin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04846881
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-24
- **Primary completion:** 2024-10-18
- **Final completion:** 2024-11-17
- **Target enrollment:** 611 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04846881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04846881, "Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04846881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*